Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL776517 | 0.82 | ALDH1A1 (0.50) | ALDH1A1GAALMNATAAR1KMT2A | |
| SCHEMBL294360 | 0.80 | ALDH1A1 (0.53) | ALDH1A1GAALMNATAAR1KMT2A | |
| SCHEMBL2376651 | 0.80 | ALDH1A1 (0.49) | ALDH1A1GAALMNATAAR1KMT2A | |
| SCHEMBL30297591 | 0.78 | CA2 (0.50) | ALDH1A1GAALMNATAAR1KMT2A | |
| SCHEMBL14378207 | 0.78 | GAA (0.47) | ALDH1A1GAALMNATAAR1KMT2A | |
| SCHEMBL4789537 | 0.78 | CA2 (0.50) | ALDH1A1GAALMNATAAR1KMT2A | |
| SCHEMBL4003591 | 0.78 | ALDH1A1 (0.47) | ALDH1A1GAALMNATAAR1KMT2A | |
| SCHEMBL2376646 | 0.78 | ALDH1A1 (0.47) | ALDH1A1GAALMNATAAR1KMT2A | |
| SCHEMBL1428960 | 0.78 | ALDH1A1 (0.47) | ALDH1A1GAALMNATAAR1KMT2A | |
| SCHEMBL294361 | 0.78 | LMNA (0.50) | ALDH1A1GAALMNATAAR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475282-B1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | HOFFMANN LA ROCHE (CH) | 2023-08-09 | — | — | EP | disclosed |
| EP-3475282-B1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | HOFFMANN LA ROCHE (CH) | 2023-08-09 | — | — | EP | disclosed |
| EP-4108665-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | F. Hoffmann-La Roche AG (CH) | 2022-12-28 | — | — | EP | disclosed |
| EP-4108665-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | F. Hoffmann-La Roche AG (CH) | 2022-12-28 | — | — | EP | disclosed |
| CN-115093418-A | [1,2,3] triazolo [4,5-d ] pyrimidine derivatives having affinity for cannabinoid type 2 receptors | 豪夫迈·罗氏有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-115073476-A | [1,2,3] triazolo [4,5-d ] pyrimidine derivatives having affinity for cannabinoid type 2 receptors | 豪夫迈·罗氏有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-113943297-A | [1,2,3] triazolo [4,5-d ] pyrimidine derivatives having affinity for cannabinoid type 2 receptors | 豪夫迈·罗氏有限公司 | 2022-01-18 | — | — | CN | disclosed |
| CN-109311886-B | [1,2,3] triazolo [4,5-d ] pyrimidine derivatives | 豪夫迈·罗氏有限公司 | 2021-11-09 | — | — | CN | disclosed |
| US-10457685-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10457685-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190127385-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127384-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127384-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
| EP-3475282-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | H. Hoffnabb-La Roche Ag (CH) | 2019-05-01 | — | — | EP | disclosed |
| EP-3475281-A1 | NOVEL [1,2,31TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2019-05-01 | — | — | EP | disclosed |
| WO-2018015088-A1 | NOVEL [1,2,31TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-25 | — | — | WO | disclosed |
| WO-2018015088-A1 | NOVEL [1,2,31TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-25 | — | — | WO | disclosed |
| WO-2017220517-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2017-12-28 | — | — | WO | disclosed |
| US-RE37094-E1 | Heterocyclic substituted acylaminothiazoles, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 2001-03-13 | — | — | US | disclosed |
| US-5189049-A | Cholecystokinin and gastrin inhibitors | SANOFI (FR) | 1993-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127384-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | CNR2, CNR1, P2RY2 | FAAH 79/4885PRSS1 4436/4885PRSS2 4027/4885 |
| US-20190127385-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | TYMS, TYMP, TBXA2R | FAAH 3114/4885PRSS1 3074/4885PRSS2 4074/4885 |
| US-10457685-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor | CNR2, CNR1, P2RY2 | FAAH 79/4885PRSS1 4436/4885PRSS2 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.